1. Home
  2. BOC vs DCTH Comparison

BOC vs DCTH Comparison

Compare BOC & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Omaha Corporation

BOC

Boston Omaha Corporation

HOLD

Current Price

$14.32

Market Cap

415.0M

Sector

N/A

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$12.85

Market Cap

372.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOC
DCTH
Founded
2009
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
415.0M
372.5M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
BOC
DCTH
Price
$14.32
$12.85
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$22.00
AVG Volume (30 Days)
167.7K
444.0K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
N/A
N/A
Revenue
$114,376,348.00
N/A
Revenue This Year
$5.79
$24.54
Revenue Next Year
$4.76
$33.15
P/E Ratio
N/A
N/A
Revenue Growth
5.64
N/A
52 Week Low
$10.52
$8.12
52 Week High
$15.22
$13.74

Technical Indicators

Market Signals
Indicator
BOC
DCTH
Relative Strength Index (RSI) 58.33 53.70
Support Level $11.95 $10.10
Resistance Level $14.35 $13.74
Average True Range (ATR) 0.41 0.52
MACD -0.03 -0.08
Stochastic Oscillator 52.38 32.04

Price Performance

Historical Comparison
BOC
DCTH

About BOC Boston Omaha Corporation

Boston Omaha Corp is a diversified holding company engaged in outdoor billboard advertising, broadband services, surety insurance, and related brokerage activities, and asset management. The company generates revenue mainly from leasing advertising space on billboards, providing broadband internet services, and earning premiums and commissions from its insurance operations. In addition, it holds minority equity investments in various businesses, including real estate-related and other industries.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: